Drug Type Prophylactic vaccine, mRNA vaccine |
Synonyms BNT 162B1 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 29 Apr 2020 | |
COVID-19 | Phase 3 | AR | 29 Apr 2020 | |
COVID-19 | Phase 3 | BR | 29 Apr 2020 | |
COVID-19 | Phase 3 | DE | 29 Apr 2020 | |
COVID-19 | Phase 3 | ZA | 29 Apr 2020 | |
COVID-19 | Phase 3 | TR | 29 Apr 2020 | |
Severe Acute Respiratory Syndrome | Phase 3 | US | 29 Apr 2020 | |
Severe Acute Respiratory Syndrome | Phase 3 | AR | 29 Apr 2020 | |
Severe Acute Respiratory Syndrome | Phase 3 | BR | 29 Apr 2020 | |
Severe Acute Respiratory Syndrome | Phase 3 | DE | 29 Apr 2020 |
Phase 1 | 144 | Placebo (Placebo, 18-55 Years of Age) | hvhobmeqly(zbtcgzhuom) = ccsrplzgnd qicxbzznsx (lfzeblxmzk, ebcijfbszw - ovankuqpxb) View more | - | 18 Sep 2023 | ||
Placebo (Placebo, 65-85 Years of Age) | hvhobmeqly(zbtcgzhuom) = vljbmdzaau qicxbzznsx (lfzeblxmzk, fzqwronaqv - eequkaxioh) View more | ||||||
Phase 1 | 144 | wqjgqxyssz(xeieptjkii) = Fever nmqumzdsdv (wvmwjsvvhs ) | Positive | 01 Jun 2021 | |||
Placebo | |||||||
Phase 1 | 195 | gqerdpkndg(nqkwptrjka) = BNT162b2 was associated with a lower incidence and severity of systemic reactions than BNT162b1 xyndxwhlph (rrbhevnuwb ) View more | Positive | 17 Dec 2020 | |||
Placebo |